BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.17.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261012
DTEND;VALUE=DATE:20261016
DTSTAMP:20260512T103447Z
CREATED:20260512T103447Z
LAST-MODIFIED:20260512T103447Z
UID:43484-1791763200-1792108799@www.pharmajournalist.com
SUMMARY:17th World ADC San Diego
DESCRIPTION:Returning as the largest and definitive ADC congress\, the 17th World ADC San Diego is THE one-stop bioconjugate shop\, bringing together the global ADC community for an unparalleled amalgamation of case studies\, development trends and networking opportunities to forge ADC innovation into differentiated\, early-line patient outcomes. \nWith 7 streams of end-to-end ADC content across Discovery Chemistry\, Discovery Biology\, Preclinical\, Translational Medicine\, Clinical Lessons\, Process & Analytical Development\, and Manufacturing & Supply\, all ADC innovation will be in the spotlight for an unmissable week of data and insights to de-risk future ADC development and push ADCs into earlier line oncology treatments. \nUniting 1\,300 industry senior enthusiasts from biopharma\, innovative start-ups\, leading service providers and academic\, physician and regulator KOLs\, World ADC San Diego is the place to discuss\, debate and advance the future of ADC development. \nFeaturing 170+ senior presenters\, a snapshot of the 2026 speaker faculty includes: \n\nSuzanne Edavettal\, Vice President\, Research & Head\, Protein Therapeutics\, Amgen\nVinod Bulusu\, Executive Director\, Product Stewardship Lead\, AstraZeneca\nGiorgia Vicentini\, Vice President\, Global Program Lead\, Oncology\, Bristol Myers Squibb\nRonald Fleming\, Executive Director\, Clinical Development\, Daiichi Sankyo\nGail Lewis\, Distinguished Scientist\, Discovery Oncology\, Genentech\nMin Hu\, Senior Vice President\, Discovery\, Innovent Biologics\nBob Lutz\, Chief Scientific Officer\, Iksuda Therapeutics\nJeffrey Settleman\, Chief Scientific Officer\, Oncology R&D\, Pfizer\nDominik Schumacher\, Chief Executive Officer\, Tubulis\nRita Nanda\, Associate Professor\, Medicine & Director\, Breast Oncology\, Section of Hematology/Oncology\, University of Chicago\n\nView the full list of speaking companies: https://ter.li/xsz013cs \nIf you want to stay competitive in the field\, you cannot miss World ADC San Diego to de-risk future ADC development and push ADCs to earlier-line oncology treatments.
URL:http://www.pharmajournalist.com/event/17th-world-adc-san-diego/
LOCATION:Town & Country San Diego\, 500 Hotel Circle\, North San Diego\, San Diego\, CA\, 92108\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261019
DTEND;VALUE=DATE:20261022
DTSTAMP:20260617T114733Z
CREATED:20260617T114733Z
LAST-MODIFIED:20260617T114733Z
UID:43761-1792368000-1792627199@www.pharmajournalist.com
SUMMARY:5th Operationalise: Early Access Programmes Summit Europe
DESCRIPTION:Early Access Programmes have evolved into a critical\, but increasingly complex\, part of drug development and launch strategy. What was once a reactive pathway is now a strategic lever shaping timelines\, evidence generation\, and patient access across global markets. \nThe 5th Operationalise: Early Access Programmes Summit Europe is built for the teams responsible for turning that strategy into execution. As regulatory expectations shift\, reimbursement timelines extend\, and programmes scale globally\, organisations must make more decisions\, earlier\, and with greater consequence. \nThis is the only European forum dedicated to the operational reality of early access – bringing together 140+ leaders across Medical Affairs\, Access\, Regulatory\, Clinical Operations\, and Supply to share how programmes are being designed\, adapted\, and delivered in practice. \nWhether you are building your first programme\, scaling across regions\, or managing a global access portfolio\, this is your opportunity to benchmark your approach\, challenge your assumptions\, and leave with the insight needed to make smarter decisions and deliver earlier\, sustainable access for patients in 2026 and beyond. \nFor more information and to register online\, please click here.
URL:http://www.pharmajournalist.com/event/5th-operationalise-early-access-programmes-summit-europe/
LOCATION:Park Plaza Victoria London\, 239 Vauxhall Bridge Road Pimlico\, London\, SW1V 1EQ\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261020
DTEND;VALUE=DATE:20261023
DTSTAMP:20260630T110639Z
CREATED:20260630T110639Z
LAST-MODIFIED:20260630T110639Z
UID:43858-1792454400-1792713599@www.pharmajournalist.com
SUMMARY:4th Covalent Drug Discovery & Development Summit
DESCRIPTION:4th Covalent Drug Discovery & Development Summit (October 20–22\, Boston\, MA) \nCovalent drug discovery is entering a defining era. Once constrained by safety and selectivity concerns\, advances in chemistry\, screening technologies\, and translational science are unlocking covalent approaches as a powerful strategy to target previously inaccessible biology. \nAs the field evolves\, the challenge is no longer proving potential. The priority is successful clinical translation. From predicting off-target toxicity to optimizing PK/PD and dose selection\, teams continue to face uncertainty when moving from discovery into the clinic. Many programs still encounter critical gaps in translating promising preclinical data into patient outcomes. \nThe 4th Covalent Drug Discovery & Development Summit is the only industry-led forum dedicated to bridging discovery through to clinical application. Designed to unite medicinal chemists\, chemical biologists\, translational scientists\, and early clinical leaders\, the meeting delivers a truly end-to-end perspective across covalent drug development\, now with expanded clinical content reflecting the growing pipeline of first-in-human and Phase II programs. \nAcross two conference days and interactive workshops\, attendees will gain practical\, actionable insights to: \n\nDesign safer\, more selective covalent compounds using novel warheads and structure-guided approaches\nDe-risk development through advanced toxicity\, reactivity\, and safety assessment strategies\nIntegrate translational data to improve in vitro to in vivo correlation and support confident clinical decisions\nExpand the druggable space by targeting new residues and previously undruggable biology\n\nWith case studies spanning AI-driven discovery\, chemoproteomics\, kinetic assays\, and translational workflows\, the summit showcases how the field is moving beyond traditional targets and into next-generation covalent therapies. \nBringing together 80+ senior leaders from pharma\, biotech\, and academia\, this is a highly curated environment for deep technical exchange\, collaboration\, and real-world problem solving. \nWhether you are optimizing discovery\, scaling translational strategy\, or preparing for the clinic\, this is the critical forum to understand what it truly takes to move covalent therapies from concept to clinic and to help shape the next wave of precision medicines.
URL:http://www.pharmajournalist.com/event/4th-covalent-drug-discovery-development-summit/
LOCATION:Hampton Inn Boston Seaport District\, 670 Summer St\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261026
DTEND;VALUE=DATE:20261030
DTSTAMP:20260609T083754Z
CREATED:20260609T083754Z
LAST-MODIFIED:20260609T083754Z
UID:43704-1792972800-1793318399@www.pharmajournalist.com
SUMMARY:9th TPD & Induced Proximity Summit
DESCRIPTION:After a decade of innovation\, the TPD field has its first drug approval in the form of Arvinas’ Veppanu. Combined with the recovering market of 2026\, this clinical validation will unleash a new wave of innovative approaches and push TPD to a new inflection point. Already\, the headwinds are reversing with $15B worth of upfront deals involving TPD candidates and companies in 2026 alone. \nHowever\, following the risk-averse funding environment of 2025\, continued positive clinical data is key to regaining investor confidence and pharma interest. That’s why the 9th TPD & Induced Proximity Summit is returning as the globe’s definitive forum to help you gain that ever-important clinical validation. As the world’s largest and most comprehensive TPD conference featuring the latest data from early discovery to clinical development\, it is designed to help you discover the best novel targets\, optimize your degrader profile\, and accelerate your pipelines to the clinic and beyond. \nView the full event guide.
URL:http://www.pharmajournalist.com/event/9th-tpd-induced-proximity-summit/
LOCATION:The Omni Boston Hotel at the Seaport\, 450 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261026
DTEND;VALUE=DATE:20261029
DTSTAMP:20260729T154123Z
CREATED:20260729T154123Z
LAST-MODIFIED:20260729T154123Z
UID:44061-1792972800-1793231999@www.pharmajournalist.com
SUMMARY:3rd Raw Materials for Cell & Gene Therapy Summit
DESCRIPTION:Cell and gene therapies are advancing into late-stage development and commercialization\, where raw materials have become a critical determinant of whether programs succeed or fail. Small inconsistencies that once went unnoticed are now triggering regulatory scrutiny\, inflating cost of goods\, and causing delays that put timelines and patient access at risk. \nFollowing the sunshine to San Diego\, the 3rd Raw Materials for Cell & Gene Therapy Summit is the only dedicated forum designed to help you take control of this risk. Through technical case studies and cross-functional discussion\, you will uncover practical\, phase-appropriate strategies to manage variability\, strengthen supplier qualification\, and build raw material frameworks that scale confidently from early development through to commercial manufacturing. \nBy joining leading experts across quality\, MSAT\, supply chain\, and process development\, you will engage in face-to-face discussions on how peers are defining material specifications\, managing lot-to-lot variability\, and making critical qualification decisions under real development pressure. \nMove on from theory and step inside the conversations shaping how raw material strategies are implemented in practice. Across technical case studies\, peer-led discussions\, and interactive workshops\, you’ll explore how teams are managing suppliers\, qualifying materials\, overseeing supply chains\, and navigating regulatory uncertainty in real-world settings. \nExplore the 2026 Agenda to Discover: \n\n19+ cross-functional experts spanning quality\, MSAT\, and supply chain shaping raw material strategies\n2 in-depth workshops to deep dive into particulate risk and material transitions before they delay your programme\nDedicated networking sessions & interactive roundtables designed to spark meaningful\, problem-solving conversations\nFace-to-face access to peers and decision-makers to exchange practical experiences not captured in published reports\n\nView the full program here to see the 19+ speaker faculty and full session details: https://ter.li/e0a0ldog
URL:http://www.pharmajournalist.com/event/3rd-raw-materials-for-cell-gene-therapy-summit/
LOCATION:The Westgate Hotel\, 1055 2nd Ave\, San Diego\, CA\, 92101\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261027
DTEND;VALUE=DATE:20261029
DTSTAMP:20260806T114332Z
CREATED:20260806T113507Z
LAST-MODIFIED:20260806T114332Z
UID:44121-1793059200-1793231999@www.pharmajournalist.com
SUMMARY:14th IMPACCT Real-World Evidence Summit
DESCRIPTION:The 14th IMPACCT Real-World Evidence Summit is the only dedicated industry forum uniting leaders across RWE\, real-world data\, evidence generation\, HEOR\, and market access to tackle the most pressing challenges in the field. From selecting regulatory-ready datasets to embedding AI and advanced analytics into workflows\, this summit focuses on how to consistently translate data into actionable decisions. \nJoin leading experts from AstraZeneca\, Pfizer\, Novartis\, Boehringer Ingelheim and more to build integrated evidence strategies\, accelerate timelines\, and maximize the ROI of real-world evidence investment. \nTo more know more visit https://ter.li/m55b0flb
URL:http://www.pharmajournalist.com/event/14th-impacct-real-world-evidence-summit/
LOCATION:Courtyard Boston Marriott Downtown\, 275 Tremont St\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261028
DTEND;VALUE=DATE:20261030
DTSTAMP:20260729T153132Z
CREATED:20260729T153132Z
LAST-MODIFIED:20260729T153132Z
UID:44054-1793145600-1793318399@www.pharmajournalist.com
SUMMARY:2nd Obesity & Weight Loss Drug Development Summit Europe
DESCRIPTION:GLP-1s changed the treatment paradigm for obesity reaching new heights of efficacy. Now\, as unmet need persists and the field looks beyond efficacy alone\, momentum is building behind therapies that can deliver lasting weight management through improved tolerability\, muscle preservation\, personalised treatment approaches\, and more convenient administration. \nAs obesity investment and pipeline activity surge across Europe\, the 2nd Obesity & Weight Loss Drug Development Summit Europe is a unique opportunity to engage with the region’s leading innovators and emerging stakeholders\, advancing the next wave of obesity therapeutics beyond first-generation GLP-1s. \nUnlike broad academic meetings\, this industry-centred forum goes beyond data headlines to explore new MoA\, combination therapies\, tolerability improvements and critical lessons to define the 2nd generation of obesity and weight loss therapeutics and strengthen Europe’s footprint in this increasingly competitive global landscape \nJoin us to shape the next era of obesity care. \nView the full event guide: https://ter.li/p453jn
URL:http://www.pharmajournalist.com/event/2nd-obesity-weight-loss-drug-development-summit-europe/
LOCATION:Hyperion Hotel Munich\, Truderinger Strasse 13\, Munich\, 81677\, Germany
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261103
DTEND;VALUE=DATE:20261124
DTSTAMP:20260709T125124Z
CREATED:20260709T125124Z
LAST-MODIFIED:20260709T125124Z
UID:43917-1793664000-1795478399@www.pharmajournalist.com
SUMMARY:10th Dermatology Drug Development Summit
DESCRIPTION:10th Dermatology Drug Development Summit – Discovering\, Developing & Commercializing Next-Generation Inflammatory Skin Disease Therapeutics – November 3-5\, 2026 | Boston\, MA \nThe 10th Dermatology Drug Development Summit returns in 2026 as the leading premier forum dedicated to advancing the discovery\, development\, and commercialization of innovative therapies for inflammatory skin disease. \nMarking a decade of convening the field’s most influential voices\, this year’s summit arrives at a pivotal moment: As competition intensifies across atopic dermatitis and psoriasis\, developers are under growing pressure to demonstrate meaningful differentiation\, accelerate development timelines and identify the next generation of high-value opportunities beyond today’s established targets and therapies. \nDesigned as an intimate\, discussion-led forum\, the summit brings together more than 90 experts spanning discovery\, translational medicine\, preclinical development\, clinical strategy\, medical affairs\, and commercial functions. \nThe meeting provides a unique opportunity to benchmark emerging science\, evaluate novel targets\, and share practical lessons from across the dermatology pipeline. \nAttendees will hear from 40+ senior leaders representing major pharmaceutical companies\, innovative biotechs\, academic research centers\, and patient advocacy organizations\, with representation from AbbVie\, Galderma\, Merck\, SUN Pharma\, Eli Lilly\, UNION Therapeutics and others. \nThis year’s agenda features dual content tracks including Discovery & Preclinical and Clinical & Commercial. \nNew additions include a Pre-Conference Workshop Day\,  offering interactive deep dives into two of dermatology’s fastest-growing areas of innovation: hidradenitis suppurativa\, exploring strategies to drive earlier intervention and disease modification\, and rare & ultra-rare inflammatory skin diseases\, examining how developers can generate meaningful evidence\, overcome translational challenges and unlock scalable opportunities across underserved patient populations. \nWith 10+ hours of in-person networking\, the summit fosters meaningful collaboration among scientists\, clinicians\, executives\, and decisionmakers working to discover\, develop and commercialize the next wave of precision therapeutics. \nFor organizations committed to shaping the future of inflammatory skin disease drug development\, the Dermatology Drug Development Summit remains the essential annual meeting to align on emerging science\, evolving standards of care\, and the path to impactful patient outcomes. \nFind out more about the 10th Anniversary Edition of the Dermatology Drug Development Summit: https://ter.li/rcr0mcj
URL:http://www.pharmajournalist.com/event/10th-dermatology-drug-development-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261113
DTSTAMP:20260703T090227Z
CREATED:20260703T090227Z
LAST-MODIFIED:20260703T090227Z
UID:43883-1794268800-1794527999@www.pharmajournalist.com
SUMMARY:9th RNA-Targeted Drug Discovery & Development Summit
DESCRIPTION:The 9th RNA-Targeted Drug Discovery & Development Summit returns to Boston\, MA\, on November 10–12\, 2026\, as the industry’s only dedicated meeting focused exclusively on RNA-targeted small molecules\, bringing together leading minds from biotech\, pharma and academia to advance the next generation of RNA-focused therapeutics. \nAs momentum continues to build across the field\, driven by recent clinical progress and increasing investment in RNA-targeted approaches\, the summit will explore the latest advances in direct RNA binding\, splice modulation\, RNA degradation\, covalent translation inhibition\, epitranscriptomic regulation and condensate biology. Attendees will gain valuable insights into how researchers are overcoming historic challenges in RNA druggability to develop new treatments for oncology\, rare genetic diseases and neurodegenerative disorders. \nA refreshed 2026 agenda will feature expert-led presentations\, case studies\, panel discussions and interactive workshops covering functional RNA target selection\, structure-guided design\, productive chemical space and emerging RNA-targeting technologies. Delegates will also discover practical strategies for improving screening approaches\, measuring selectivity\, validating targets and accelerating translation from discovery into clinical development. \nThe summit is expected to welcome 80+ RNA-targeted drug discovery experts and 22+ world-class speakers\, including representatives from PTC Therapeutics\, AstraZeneca\, Sanofi\, ReviR Therapeutics\, Remix Therapeutics\, Arrakis Therapeutics\, Dewpoint Therapeutics and Syrna Therapeutics. Through dedicated networking opportunities and collaborative discussions\, attendees will connect with the scientists\, innovators and decision-makers shaping the future of RNA-targeted medicines. \nWhether you are focused on RNA biology\, medicinal chemistry\, drug discovery\, translational research or therapeutic development\, this summit offers an unparalleled opportunity to access cutting-edge data\, exchange ideas with pioneers in the field and help drive the next wave of innovation in RNA-targeted small molecule therapeutics. As the field continues to mature\, the 9th RNA-Targeted Drug Discovery & Development Summit remains the must-attend forum for staying at the forefront of RNA drug discovery.
URL:http://www.pharmajournalist.com/event/9th-rna-targeted-drug-discovery-development-summit/
LOCATION:Hotel Commonwealth\, 500 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261113
DTSTAMP:20260709T124430Z
CREATED:20260709T124339Z
LAST-MODIFIED:20260709T124430Z
UID:43911-1794268800-1794527999@www.pharmajournalist.com
SUMMARY:9th Lab Asset & Facility Management Summit
DESCRIPTION:The 9th Lab Asset & Facility Management (LAFM) Summit 2026 is the leading industry forum dedicated to helping pharmaceutical and biotech organizations optimize lab operations\, asset management\, facilities\, engineering\, and research infrastructure. Taking place in Boston\, MA from November 10–12\, 2026\, the flagship event brings together 190+ senior leaders and decision-makers responsible for creating efficient\, resilient\, and high-performing R&D environments. \nAs scientific research becomes increasingly complex and organizations face growing pressure to do more with less\, LAFM provides a unique platform to explore practical strategies that improve operational efficiency\, maximize asset performance\, strengthen cross-functional collaboration\, and ultimately give scientists more time to focus on breakthrough research. \nJoin us to gain actionable insights through over 28 real-world case studies\, interactive discussions\, peer-to-peer benchmarking\, and hands-on workshops designed to address the most pressing challenges facing lab operations and facility management teams today. The agenda features dedicated content covering both laboratory operations and site-wide management\, helping attendees discover proven approaches to streamlining workflows\, improving maintenance strategies\, enhancing asset visibility\, and building more future-ready research environments. \nThe 2026 agenda also introduces innovative networking and learning formats\, including the LAFM Exchange and the R&D Operations Action Day\, giving participants more opportunities to engage with peers\, share experiences\, and leave with practical frameworks they can implement immediately within their own organizations. \nBringing together experts from leading organizations including Pfizer\, Takeda\, Novartis\, Regeneron\, Sanofi\, Boehringer Ingelheim\, Gilead Sciences\, and Eli Lilly\, LAFM offers an unrivalled opportunity to connect with the people shaping the future of laboratory and facility operations across the life sciences industry. Whether your goal is to increase operational efficiency\, improve facility performance\, support scientific teams more effectively\, or benchmark your strategy against industry leaders\, LAFM is the place to learn\, connect\, and drive meaningful impact across your organization. \nTo know more visit: https://ter.li/mnzyk67w
URL:http://www.pharmajournalist.com/event/9th-lab-asset-facility-management-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261113
DTSTAMP:20260709T143647Z
CREATED:20260709T143647Z
LAST-MODIFIED:20260709T143647Z
UID:43936-1794268800-1794527999@www.pharmajournalist.com
SUMMARY:World Cell & Gene Therapy Summit South Korea
DESCRIPTION:South Korea’s cell and gene therapy landscape is highly dynamic\, as observed from regulatory approvals\, clinical trial progress\, and manufacturing activity\, from over 150 companies in active drug development. Additionally\, with global pharma including Bayer\, Novartis and more seeing strategic investments into the CGT space within South Korea\, greater opportunities for scientific innovation and technology advancement are yet to come. \nThe inaugural World Cell & Gene Therapy Summit South Korea is an exclusive opportunity to connect with global pharma and leading Korean biotech showcasing the latest trends in autologous\, allogeneic\, in vivo\, and gene editing therapies to help you identify gaps within your programs and set the roadmap of CGT development in 2026/2027. \nOne Pass\, Two Events: Part of the World Advanced Therapeutics Summit South Korea organized by Hanson Wade\, this event offers a platform for cross-learning and connections with experts working in RNA and vaccine development and together establish South Korea as a global hub for advanced biopharma innovation.
URL:http://www.pharmajournalist.com/event/world-cell-gene-therapy-summit-south-korea/
LOCATION:Grand Hyatt Incheon\, 208 Yeongjonghaeannam-ro 321beon-gil\, Jung-gu\, Incheon\, South Korea
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261113
DTSTAMP:20260709T144427Z
CREATED:20260709T144427Z
LAST-MODIFIED:20260709T144427Z
UID:43942-1794268800-1794527999@www.pharmajournalist.com
SUMMARY:2nd World RNA-Based Therapeutics & Vaccines Summit South Korea
DESCRIPTION:Driven by South Korea’s government making strategic investments in mRNA platforms and growing collaboration between global pharma and local biotech innovators\, the field is experiencing renewed development momentum. This is placing the region as a key hotspot for global mRNA innovation and interest. \nUniquely positioned as the industry’s most comprehensive biopharma forum\, the 2nd World RNA-Based Therapeutic & Vaccine Summit South Korea brings together global and local leaders to share first-hand insights into cutting-edge mRNA modalities\, delivery technologies\, and manufacturing excellence\, to progress mRNA medicines to patients faster. \nOne Pass\, Two Events: Part of the World Advanced Therapeutics Summit South Korea organized by Hanson Wade\, this event offers a platform for cross-learning and connections with experts working in cell and gene therapies and together establish South Korea as a global hub for advanced biopharma innovation.
URL:http://www.pharmajournalist.com/event/2nd-world-rna-based-therapeutics-vaccines-summit-south-korea/
LOCATION:Grand Hyatt Incheon 208 Yeongjonghaeannam-ro\, 321 Beon-gil\, Yeongjong-gu\, 23358\,  Incheon South Korea
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261116
DTEND;VALUE=DATE:20261118
DTSTAMP:20260805T093959Z
CREATED:20260804T140412Z
LAST-MODIFIED:20260805T093959Z
UID:44087-1794787200-1794959999@www.pharmajournalist.com
SUMMARY:Biomarker Operations & Biospecimen Management Summit
DESCRIPTION:Hot off the press: The biomarker operations and biospecimen community finally has its own dedicated forum. \nIntroducing the inaugural Biomarker Operations & Biospecimen Management Summit\, the industry’s first\, purpose-built meeting for the heads\, VPs and leading stakeholders at pharma and biotech directly responsible for biospecimen and biomarker delivery. \nView the newly released agenda:  https://ter.li/p9sor70u \nWith trials growing in complexity\, rapidly expanding globally and becoming more data-intensive\, biomarker operations has emerged as the critical function for teams looking to advance biomarker- and multi-omics-driven therapies to market. \nAnswering the industry’s call to unite those collecting\, tracking and/or translating biospecimen data\, this meeting arrives at a pivotal moment. \nYou can expect to join 80+ experts to strategize on: \n\nElevating pre-analytical quality and site collection practices\, protecting biomarker signal integrity from the very first draw\nSecuring and storing biospecimens for the long term\, building acquisition\, biobanking\, and disposition strategies that balance cost\, compliance\, and future scientific value\nStreamlining biosample logistics\, kit management and vendor sourcing\, cutting waste and tracking errors so every sample reaches the right lab\, on time\nNavigating consent complexity and evolving regulation\, including IVDR and ICH E6(R3)\, to keep biospecimens compliant and usable for research\, long after collection\nEmbedding FAIR data principles and AI-driven automation into biomarker workflows\, replacing manual reconciliation with systems that accelerate decision-making\n\nAlongside this\, hear best-in-class strategies from AstraZeneca\, Regeneron\, Moderna\, BioNTech\, and Bristol Myers Squibb and real-time updates from Biospecimen Management Consortium (BMC). \nJoin us in collaboratively building the future playbook that will define the standards for precision medicine therapies. \nRegistration is complimentary* for qualifying biopharma and researchers. Visit the website to reserve your spot: https://ter.li/6v47cb7t
URL:http://www.pharmajournalist.com/event/biomarker-operations-biospecimen-management-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261117
DTEND;VALUE=DATE:20261120
DTSTAMP:20260813T160131Z
CREATED:20260813T160131Z
LAST-MODIFIED:20260813T160131Z
UID:44184-1794873600-1795132799@www.pharmajournalist.com
SUMMARY:2nd Model-Informed Drug Development Summit 2026
DESCRIPTION:As model-informed drug development (MIDD) becomes increasingly central to modern drug development strategy\, organizations are under growing pressure to leverage quantitative approaches that accelerate timelines\, reduce risk\, and improve regulatory and clinical success. The 2nd Model-Informed Drug Development Summit\, taking place November 17-19\, 2026\, in Boston\, MA\, brings together senior leaders in pharmacometrics\, clinical pharmacology\, quantitative sciences\, translational medicine\, and regulatory science to explore how modelling is transforming decision-making across the entire development lifecycle. \nDesigned as an intimate and highly interactive forum\, this summit moves beyond traditional large-scale industry meetings to provide meaningful peer-to-peer networking\, practical case studies\, and candid discussions on the real-world challenges of implementing MIDD strategies. Attendees will gain insights from leading organizations including FDA\, Health Canada\, Sanofi\, Eli Lilly\, GSK\, AbbVie\, Novartis\, Amgen\, Genentech\, Gilead Sciences\, BMS\, Astellas Pharma\, Vertex Pharmaceuticals\, Johnson & Johnson\, and Genmab. \nThe agenda explores the latest industry developments\, including implementation of the finalized ICH M15 guideline\, the growing role of quantitative systems pharmacology (QSP)\, advances in AI-enabled modelling\, and the use of real-world evidence to strengthen development decisions. Through case studies\, panel discussions\, workshops\, and roundtable sessions\, attendees will learn how to optimize dose selection\, improve trial design\, accelerate rare disease programs\, validate model outputs\, demonstrate return on investment from MIDD initiatives\, and strengthen regulatory submissions. \nIn addition to the main conference\, dedicated workshops will examine how to integrate pharmacometrics\, QSP\, machine learning\, and AI into connected modelling ecosystems\, while also addressing the challenge of building internal and external stakeholder confidence in modelling approaches. \nWith more than 60 senior industry leaders expected to attend\, the summit offers a unique opportunity to benchmark strategies\, share best practices\, build valuable partnerships\, and stay ahead of evolving regulatory and scientific expectations. Whether you are advancing innovative therapies\, refining quantitative development strategies\, or exploring the future role of AI in drug development\, this event provides the practical insights and connections needed to maximize the impact of model-informed approaches across your organization. \nTo learn more about the event and register online click here.
URL:http://www.pharmajournalist.com/event/2nd-model-informed-drug-development-summit-2026/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261203
DTSTAMP:20260811T120601Z
CREATED:20260811T103702Z
LAST-MODIFIED:20260811T120601Z
UID:44144-1795996800-1796255999@www.pharmajournalist.com
SUMMARY:Novel CNS Biomarkers Summit Europe
DESCRIPTION:Introducing Europe’s first CNS Biomarker Forum. The Novel CNS Biomarkers Summit Europe is the only European meeting dedicated exclusively to advancing fluid\, imaging\, and digital biomarkers for CNS drug development. Bringing together biomarker\, translational medicine\, neuroscience\, and clinical development leaders\, the summit focuses on accelerating the discovery\, validation\, and implementation of next-generation biomarkers across neurodegenerative and neurological diseases. \nAs landmark advances in blood-based Alzheimer’s diagnostics\, digital biomarkers\, multimodal approaches\, and precision medicine continue to reshape the field\, attendees at the Novel CNS Biomarkers Summit Europe will explore strategies to improve patient stratification\, demonstrate target engagement\, generate earlier efficacy signals\, and de-risk CNS drug development programmes. \nCompanies attending the Novel CNS Biomarkers Summit Europe: \n\nRoche\n\n\nUCB\n\n\nLundbeck\n\n\nServier\n\n\nNRG Therapeutics\n\n\nImmunic Therapeutics\n\n\nProgenra\n\n\nSaniona\n\n\nBial\n\n…and more! \nWhy attend the Novel CNS Biomarkers Summit Europe? \n\nJoin 60+ biomarker and translational medicine leaders\n\n\nGain insights from 17+ expert speakers\n\n\nExplore biomarker strategies across 6+ CNS indications\n\n\nParticipate in interactive workshops and networking opportunities\n\nDiscover the brand-new event programme now for more information on sessions and how to register your place.
URL:http://www.pharmajournalist.com/event/novel-cns-biomarkers-summit-europe/
LOCATION:The Hilton London Olympia\, 380 Kensington High St\, Kensington\, London\, W14 8N\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261204
DTSTAMP:20260805T090545Z
CREATED:20260805T090501Z
LAST-MODIFIED:20260805T090545Z
UID:44111-1796083200-1796342399@www.pharmajournalist.com
SUMMARY:8th CNS Drug Delivery Summit
DESCRIPTION:The 8th CNS Drug Delivery Summit is the leading industry forum dedicated to overcoming the challenges of delivering therapeutics across the blood-brain barrier and into the central nervous system. \nBringing together experts from biopharma\, biotech\, and academia\, the summit will explore the latest advances in drug delivery technologies\, including nanoparticles\, antibody shuttles\, gene therapy vectors\, focused ultrasound\, and intranasal delivery. Attendees will gain practical insights into improving drug penetration\, optimising biodistribution\, and advancing therapies for neurological and neurodegenerative diseases. \nThrough scientific presentations\, case studies\, and interactive discussions\, the event will address key translational\, clinical\, manufacturing\, and regulatory challenges while showcasing innovative approaches that can accelerate CNS drug development. \nJoin a collaborative community of drug developers\, technology innovators\, and scientific leaders committed to unlocking the next generation of CNS therapies and improving outcomes for patients worldwide. \nFind out more today: https://ter.li/08gi5jio
URL:http://www.pharmajournalist.com/event/8th-cns-drug-delivery-summit/
LOCATION:Hyatt Regency Boston Harbor\, 101 Harborside Drive\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261208
DTEND;VALUE=DATE:20261211
DTSTAMP:20260813T155514Z
CREATED:20260813T155514Z
LAST-MODIFIED:20260813T155514Z
UID:44179-1796688000-1796947199@www.pharmajournalist.com
SUMMARY:World CNS Summit South Korea
DESCRIPTION:The World CNS Summit South Korea is the premier industry-focused forum dedicated to advancing targeted\, mechanism-differentiated therapies for neurodegenerative\, rare neurodevelopmental\, and neuropsychiatric disorders. As South Korea emerges as a major center for neuroscience innovation\, the summit convenes biopharma leaders\, translational scientists\, and drug developers to explore the next generation of CNS therapeutics and accelerate progress from discovery through early clinical development. \nThe agenda highlights advances in disease-modifying approaches\, blood-brain barrier delivery technologies\, RNA-based therapeutics\, gene therapies\, neuroinflammation\, biomarkers\, and novel targets beyond traditional amyloid and tau pathways. Attendees will gain insights from leading organizations including ABL Bio\, AriBio\, Johnson & Johnson\, Eli Lilly\, Novartis\, Takeda\, AbbVie\, Lundbeck\, Angelini Pharma and many more. \nDesigned to foster meaningful scientific exchange and strategic collaboration\, the summit provides a valuable platform to connect with Korean biotech innovators\, global pharmaceutical companies\, and external innovation leaders evaluating the next wave of CNS opportunities. For decision-makers shaping neuroscience pipelines\, partnerships\, and licensing strategies\, it offers a focused view of the technologies\, modalities\, and therapeutic approaches driving the future of CNS drug development. \nFind out more today: https://ter.li/jrf94t4n
URL:http://www.pharmajournalist.com/event/world-cns-summit-south-korea/
LOCATION:Grand Hyatt Incheon 208 Yeongjonghaeannam-ro\, 321 Beon-gil\, Yeongjong-gu\, 23358\,  Incheon South Korea
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261208
DTEND;VALUE=DATE:20261211
DTSTAMP:20260813T160546Z
CREATED:20260813T160546Z
LAST-MODIFIED:20260813T160546Z
UID:44189-1796688000-1796947199@www.pharmajournalist.com
SUMMARY:10th Complement-Based Drug Development Summit
DESCRIPTION:The 10th Complement-Based Drug Development Summit returns at a pivotal moment as the field shifts from validating complement biology to maximizing its clinical and commercial potential. As pipelines expand beyond C3 and C5 and competition intensifies\, developers are focused on identifying the right targets\, modalities\, and indications to drive differentiation and patient impact. Recent milestones\, including Regeneron’s cemdisiran advancing through FDA and EMA review and Biogen’s acquisition of Apellis\, highlight the growing momentum and investment shaping the next era of complement therapeutics. \nAs the industry’s only dedicated forum uniting complement leaders\, this meeting will address the strategic and scientific priorities shaping the next generation of complement therapeutics\, including: \n\nAdvancing clinical success through biomarker innovation\, improved target engagement strategies\, robust trial design\, and smarter indication selection to de-risk development\n\n\nBenchmarking next-generation modalities across siRNA\, gene therapy\, biologics\, and novel delivery technologies to improve durability\, efficacy\, safety\, and patient outcomes\n\n\nExpanding beyond C3 and C5 to evaluate intracellular complement biology\, emerging targets\, novel mechanisms\, and combination approaches shaping the next generation of complement therapeutics\n\n\nUnlocking growth beyond renal disease by assessing the translational and clinical opportunity across neurodegenerative\, ocular\, autoimmune\, haematological\, oncology\, and acute indications\n\nWhat to Expect: \n\n80+ Experts Dedicated to Complement\n\n\n18+ Data-Driven Presentations\n\n\n7+ Hours of Meaningful Networking\n\n\n2 Discussion-Led Workshops\n\n\n1 Scientific Poster Session\n\nBringing together biotech innovators\, pharma leaders\, and academic KOLs\, this industry-led anniversary meeting provides a focused opportunity to advance novel targets\, refine modality strategy\, navigate clinical development\, and expand into new indications. \nBy attending\, you’ll be in the room with: Annexon Biosciences\, Apellis Pharmaceuticals\, Cascade Biotechnology\, Complement Therapeutics\, Graviton Biosciences\, Genentech\, Grid Therapeutics\, Ikarovec\, Inflarx\, Regeneron\, Ripple Therapeutics\, Sanofi and more! \nAcross 3 days of discussion-led workshops\, data-driven presentations\, clinical insights\, and expert panels\, engage with the leaders behind renal readouts\, next-generation targets\, and emerging CNS and ophthalmology programs to benchmark your approach\, strengthen differentiation\, and build partnerships that de-risk complement drug development. \nDiscover the 10th Anniversary Meeting program here: https://ter.li/2yscb7oh
URL:http://www.pharmajournalist.com/event/10th-complement-based-drug-development-summit/
LOCATION:Hotel Commonwealth\, 500 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR